Gapping up
In reaction to strong earnings/guidance: THLD +65%, SSKN +29.1%, PFNX+21.9%, SNC +17.6%, SGRY +15.8%, ULTA +13.9%, (Ulta Salon also announces $200 mln accelerated share repurchase plan), NVEE +13.2%,FNSR +12.8%, MMI +9.6%, BOJA +9.6%, KTOS +7.9%, CNTY +7.7%, ATHX+6%, SYN +5.4%, FPRX +5.2%, PGNX +3.6%, CMTL +2.6%, ABTL +1.4%, GSVC+1.3%, PAY +0.8%, VNET +0.8%, AGFS +0.6%, VRNG +0.5%
M&A news: FCTY +30.6% (to be acquired by MidFirst Bank for $11.22 per share in cash), LPSB +10% (to be acquired by Horizon Bancorp (HBNC) for $17.50 per share), JMEI +1.9% (formed special committee to consider non-binding 'going private' proposal of $7/ADS that the Board received on February 17)
Select EU financial related names showing strength: DB +4.5%, CS +4.1%,SAN +4.1%, ING +3.9%, BBVA +3.3%, RBS +3.3%
Select oil/gas related names showing strength: SDRL +8.7%, SN +5.7%, WLL+4.4%, CHK +3.5%, COP +2.2%, DVN +1.9%
Other news: SPPI +16.8% (receives notification from the FDA of the grant of approval of the NDA for EVOMELA for Injection for use in two indications),BCEI +2.9% (elected to draw down $209 million on its credit facility), NFLX+2.5% (still checking, may be rebounding after yesterday's underperformance), SUNE +1.7% (names Ilan Daskal as CFO designee, effective no later than April ), SNY +1.4% (Regeneron Pharma and Sanofi report Topline Results of Phase 3 Monotherapy Study met primary endpoint),JCOM +1.2% (responds to Citron's report, calling it 'factually incorrect and wrongly critical'), AMGN +0.5% (supplemental biologics license application accepted by the FDA for expanded use of Enbrel to treat pediatric patients with chronic severe plaque psoriasis)
Analyst comments: OAS +5% (upgraded to Neutral from Sell at Goldman),BETR +3.9% (upgraded to Buy from Neutral at Goldman), X +1.7% (initiated with an Outperform at Credit Suisse ), APC +1.6% (upgraded to Buy from Neutral at Goldman), CVX +1% (upgraded to Neutral from Sell at Goldman)
In reaction to strong earnings/guidance: THLD +65%, SSKN +29.1%, PFNX+21.9%, SNC +17.6%, SGRY +15.8%, ULTA +13.9%, (Ulta Salon also announces $200 mln accelerated share repurchase plan), NVEE +13.2%,FNSR +12.8%, MMI +9.6%, BOJA +9.6%, KTOS +7.9%, CNTY +7.7%, ATHX+6%, SYN +5.4%, FPRX +5.2%, PGNX +3.6%, CMTL +2.6%, ABTL +1.4%, GSVC+1.3%, PAY +0.8%, VNET +0.8%, AGFS +0.6%, VRNG +0.5%
M&A news: FCTY +30.6% (to be acquired by MidFirst Bank for $11.22 per share in cash), LPSB +10% (to be acquired by Horizon Bancorp (HBNC) for $17.50 per share), JMEI +1.9% (formed special committee to consider non-binding 'going private' proposal of $7/ADS that the Board received on February 17)
Select EU financial related names showing strength: DB +4.5%, CS +4.1%,SAN +4.1%, ING +3.9%, BBVA +3.3%, RBS +3.3%
Select oil/gas related names showing strength: SDRL +8.7%, SN +5.7%, WLL+4.4%, CHK +3.5%, COP +2.2%, DVN +1.9%
Other news: SPPI +16.8% (receives notification from the FDA of the grant of approval of the NDA for EVOMELA for Injection for use in two indications),BCEI +2.9% (elected to draw down $209 million on its credit facility), NFLX+2.5% (still checking, may be rebounding after yesterday's underperformance), SUNE +1.7% (names Ilan Daskal as CFO designee, effective no later than April ), SNY +1.4% (Regeneron Pharma and Sanofi report Topline Results of Phase 3 Monotherapy Study met primary endpoint),JCOM +1.2% (responds to Citron's report, calling it 'factually incorrect and wrongly critical'), AMGN +0.5% (supplemental biologics license application accepted by the FDA for expanded use of Enbrel to treat pediatric patients with chronic severe plaque psoriasis)
Analyst comments: OAS +5% (upgraded to Neutral from Sell at Goldman),BETR +3.9% (upgraded to Buy from Neutral at Goldman), X +1.7% (initiated with an Outperform at Credit Suisse ), APC +1.6% (upgraded to Buy from Neutral at Goldman), CVX +1% (upgraded to Neutral from Sell at Goldman)